"Health News - Medicine, Diet and Fitness"

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.

Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.

(more…)

(Ivanhoe Newswire) — A natural hormone could someday be used to make better, safer treatments for hypertension. Traditional hypertension drugs that lower sodium levels have serious side effects because they also reduce potassium levels.

For years scientists have thought there was a natural hormone that could safely flush sodium out of the body and be used to develop more effective and safer treatments for high blood pressure. Now researchers at Cornell University and the Boyce Thompson Institute for Plant Research say they have discovered such a hormone.

Researchers developed a new technique for analyzing complex mixtures of small molecules – urine contains a mix of hundreds of molecules. This made it possible to finally identify the hormone.

(more…)

Thirteen states this year have seen legislative proposals aimed at limiting financial relationships between physicians and drugmakers. Most bills failed to pass, due to heavy pressure from pharmaceutical lobbyists, experts said, but new efforts are afoot.

The latest proposals include a Michigan bill that would make that state the second in the nation after Minnesota to place a limit — $100 — on the total value of gifts a drugmaker can give a physician in a year. Michigan and Massachusetts are considering so-called sunshine laws requiring drug companies to publicly disclose any gifts, payments, subsidies or incentives worth more than $25.

(more…)